Lexeo Therapeutics is a clinical-stage genetic medicine company headquartered in New York City, pioneering cardiac genetic medicine candidates to treat the root causes of inherited cardiovascular diseases. Our lead program, LX2006, targets cardiomyopathy associated with Friedreichâs Ataxia and anchors a broader pipeline addressing genetically defined conditions such as hypertrophic and arrhythmogenic cardiomyopathies. Backed by a strong financial foundation, Lexeo is positioned to translate groundbreaking science into durable clinical impact. This internship sits at the intersection of artificial intelligence, machine learning, and clinical drug development. You will work directly with Lexeoâs clinical and scientific leadership to design and execute data-driven analyses using real clinical study data. The overarching goal is to generate novel insights that inform our understanding of: Disease burden and progression in rare cardiovascular conditions Mechanisms of action of AAV-based gene therapies in human subjects Novel clinical endpoints and biomarkers that could strengthen future study designs This is hands-on, hypothesis-driven R&D work. You will not be running pre-packaged reports or prompting general-purpose AI tools â you will be building and deploying analytical pipelines, training models, and contributing to scientific interpretation alongside domain experts.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Career Level
Intern
Education Level
No Education Listed
Number of Employees
11-50 employees